StockData
Novartis AG logo

Novartis AG

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30
$160.79−0.31 (-0.19%)

Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –

Novartis Tafinlar + Mekinist (dabrafenib + trametinib by Quarter

Tafinlar + Mekinist (dabrafenib + trametinib — melanoma & BRAF-mutated cancers) ($M)

QuarterlyAnnual

Novartis Tafinlar + Mekinist (dabrafenib + trametinib: $570M in Q3 2026, up 3.6% from a year earlier.

Latest, Q3 2026
570
Period ended Sep 30, 2026
Change on a year earlier
+3.6%
550 in Q3 2025
History
35 quarters
Since Q4 2017
Sources
27
Documents cited below

Where the Q3 2026 figure comes from

“|| Tafinlar + Mekinist | 570 | 550 | 4 | 4”

Source: Novartis Form 6-K (0001114448-26-000014) ↗

Reported in Form 6-K & Form 20-F.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedTafinlar + Mekinist (dabrafenib + trametinib — melanoma & BRAF-mutated cancers) ($M)Year on yearSource
Q3 2026Sep 30, 2026570+3.6%Novartis Form 6-K (0001114448-26-000014) ↗
Q2 2026Jun 30, 2026581+1.4%Novartis Form 6-K (0001114448-26-000012) ↗
Q1 2026Mar 31, 2026493-10.7%Novartis Form 6-K (0001114448-26-000010) ↗
Q4 2025Dec 31, 2025540+2.5%Novartis Form 6-K (0001114448-26-000007) ↗
Q3 2025Sep 30, 2025550+3.0%Novartis Form 6-K (0001114448-26-000014) ↗
Q2 2025Jun 30, 2025573+9.6%Novartis Form 6-K (0001114448-26-000012) ↗
Q1 2025Mar 31, 2025552+16.5%Novartis Form 6-K (0001114448-26-000010) ↗
Q4 2024Dec 31, 2024527+8.4%Novartis Form 6-K (0001114448-26-000007) ↗
Q3 2024Sep 30, 2024534+10.8%Novartis Form 6-K (0001114448-25-000003) ↗
Q2 2024Jun 30, 2024523+5.4%Novartis Form 6-K (0001370368-25-000012) ↗
Q1 2024Mar 31, 2024474+3.5%Novartis Form 6-K (0001370368-25-000010) ↗
Q4 2023Dec 31, 2023486+4.5%Novartis Form 6-K (0001370368-25-000007) ↗
Q3 2023Sep 30, 2023482+7.1%Novartis Form 6-K (0001370368-24-000022) ↗
Q2 2023Jun 30, 2023496+9.7%Novartis Form 6-K (0001370368-24-000019) ↗
Q1 2023Mar 31, 2023458+13.6%Novartis Form 6-K (0001370368-24-000017) ↗
Q4 2022Dec 31, 2022465+1.5%Novartis Form 6-K (0001370368-24-000007) ↗

Breakdown

What makes up tafinlar + Mekinist (dabrafenib + trametinib

Cite this data

StockData. (2026). Novartis Tafinlar + Mekinist (dabrafenib + trametinib ($M), quarterly Q4 2017–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-tafinlar-mekinist

See every metric in the Novartis KPI table. Data updated Nov 2, 2026.